Data Sheet | April 2, 2026
NULISAseq™ Neuro 220 Panel
Get the Resource
Download NowSapient offers the NULISAseq Neuro 220 Panel to enable high‑resolution, multiplexed measurement of 220 protein biomarkers known as the hallmarks of neurogenerative disease. This single panel provides a systems‑level view of neurodegenerative biology in human cohorts, unlocking co-pathologies in neurodegeneration and detecting heterogeneity in response to therapeutics.
The Neuro 220 Panel extends the suite of biomarkers covered in the NULISAseq CNS Disease Panel 120, offering the broadest coverage of tau isoforms including both brain-derived and peripheral species. It also features additional biomarkers associated with Parkinson’s Disease (PD), developed in collaboration with the Michael J. Fox Foundation (MJFF) for Parkinson’s Research.
Through comprehensive analysis of amyloid and tau pathology, synuclein biology, neuroinflammation, vascular dysfunction, synaptic integrity, and metabolic stress, the NULISAseq Neuro 220 Panel enables researchers to move beyond narrow frameworks and capture the biological complexity underlying diseases such as Alzheimer’s disease, PD, traumatic brain injury (TBI), multiple sclerosis (MS), and gliomas.
Download the data sheet to learn how the NULISAseq Neuro 220 Panel provides:
- Quantitative measurement of 220 biomarkers associated with neurodegeneration from a single 25 µL sample
- The broadest coverage of tau isoforms, including brain-derived and peripheral isoforms of total tau and phosphorylated species (pTau217, pTau181, pTau205, pTau212, and pTau231) in a single panel
- Novel content for PD developed in collaboration with MJFF
- Applicability to a broad range of neurodegenerative disease research
As a Certified Service Provider of Alamar Biosciences NULISA™ panels and assays, Sapient has proven expertise in Alamar’s technologies and a track record for delivering rapid, reproducible results that inform key decisions in CNS disease research programs.
We also offer the unique ability to both analyze your samples and validate the findings in independent real-world cohorts using our DynamiQ™ molecular-clinical database – as well as to layer additional multi-omics data to orthogonally validate and extend NULISA findings.